Please login to the form below

Not currently logged in
Email:
Password:

XenoGesis appoints business development consultant

Sabrina Mogle will spearhead CRO’s US growth

XenoGesis Sabrina MogleNottingham, UK-headquartered XenoGesis has appointed business development consultant Sabrina Mogle to drive the contract research organisation's growth in the US.

Bringing expertise in business and corporate development in the biotech and pharma industries, Mogle will spearhead XenoGesis' US business development strategy and industry awareness profile.

Richard Weaver, managing director of XenoGesis, said: “Sabrina's appointment supports our growth strategy to open up the US market. We already have a number of clients in the US and have identified the opportunity to grow our business further in the US.

“We are excited to welcome Sabrina to the team and her experience, knowledge and understanding of drug development and regulatory affair in the US will be a valuable addition to our business.”

Currently, Mogle serves as chief executive officer of RareMoon Consulting, a non-clinical development and regulatory affairs consulting firm specialising in orphan drugs she co-founded earlier this year.

She has previously held director-level roles at US biotechs NovusLife and Cote Orphan, and US CROs Toxikon Corporation and XenoTech.

Mogle said: “XenoGesis is an exciting, fast-growing and ambitious business and is developing an enviable reputation in the preclinical DMPK space for its consultative approach with clients.

“I am delighted to be part of the team and play my part in supporting the next stage growth.”

22nd September 2016

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics